More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling.
Bader P, Salzmann-Manrique E, Balduzzi A, Dalle JH, Woolfrey AE, Bar M, Verneris MR, Borowitz MJ, Shah NN, Gossai N, Shaw PJ, Chen AR, Schultz KR, Kreyenberg H, Di Maio L, Cazzaniga G, Eckert C, van der Velden VHJ, Sutton R, Lankester A, Peters C, Klingebiel TE, Willasch AM, Grupp SA, Pulsipher MA.
Bader P, et al. Among authors: balduzzi a.
Blood Adv. 2019 Nov 12;3(21):3393-3405. doi: 10.1182/bloodadvances.2019000449.
Blood Adv. 2019.
PMID: 31714961
Free PMC article.